Novel insights into the anti-cancer effects of 3-bromopyruvic acid against castration-resistant prostate cancer

CNU IR > College of Smart Living > Dept. of Senior Service and Health Management > Periodical Articles > Item 310902800/34581

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34581

Title:	Novel insights into the anti-cancer effects of 3-bromopyruvic acid against castration-resistant prostate cancer
Authors:	Yeh, Hsin-Chih Su, Chia-Cheng Wu, Yen-Hsuan Lee, Cheng Hsueh Bao, Bo-Ying Cheng, Wei-Chung Wang, Shu-Chi Liu, Po-Len Chiu, Chien-Chih Chuu, Chih-Pin Ke, Chien-Chih Wu, Hsin-En Chen, Yuan-Ru Chung, Wei-Ju Huang, Shu-Pin Li, Chia-Yang
Contributors:	Kaohsiung Medical University Kaohsiung Medical University Hospital Kaohsiung Municipal Ta-Tung Hospital Chi Mei Hospital Department of Senior Citizen Service Management, Chia Nan University of Pharmacy & Science China Medical University Taiwan China Medical University Hospital - Taiwan Asia University Taiwan China Medical University Taiwan Kaohsiung Medical University National Health Research Institutes - Taiwan
Keywords:	cell-cycle arrest apoptosis therapy agent model mcf-7 line
Date:	2022
Issue Date:	2023-12-11 13:59:00 (UTC+8)
Publisher:	ELSEVIER
Abstract:	3-bromopyruvic acid (3-BP), a small molecule alkylating agent, has been emerged as a glycolytic inhibitor with anticancer activities. However, the effects of 3-BP on the growth and metastasis in prostate cancer have not been well investigated. Here we investigated the anti-cancer effects of 3-BP on prostate cancer in vitro and in vivo. Cell growth, apoptosis, migration, motility, and invasion were examined. The tumor growth ability was determined using a xenograft murine model. Transcriptome analysis using RNA-seq was performed to explore the mechanism of action of 3-BP. Our experimental results showed that 3-BP effectively inhibits prostate cancer cell growth, especially in castration-resistant prostate cancer (CRPC) cells. Moreover, 3-BP induces apoptosis and suppresses cell migration, motility, epithelial-mesenchymal transition (EMT), and invasion in CRPC cells. In addition, 3-BP also attenuates tumor growth in a xenograft murine model. Through transcriptome analysis using RNA-seq, 3-BP significantly regulates the cell cycle pathway and decreases the expression of downstream cycle cycle-associated genes in CRPC cells. The results of cell cycle analysis indicated that 3-BP arrests cell cycle progression at G2/M in CRPC cells. These results suggest that 3-BP has the potential in inhibiting CRPC progression and might be a promising drug for CRPC treatment.
Relation:	EUROPEAN JOURNAL OF PHARMACOLOGY, v.923,174929CB2
Appears in Collections:	[Dept. of Senior Service and Health Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	153	View/Open

Loading...